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Serum opacity factor (SOF) is a virulence determinant expressed by a variety of streptococcal and staphylococcal species including
both human and animal pathogens. SOF derives its name from its ability to opacify serum where it targets and disrupts the
structure of high-density lipoproteins resulting in formation of large lipid vesicles that cause the serum to become cloudy. SOF is a
multifunctional protein and in addition to its opaciﬁcation activity, it binds to a number of host proteins that mediate adhesion of
streptococci to host cells, and it plays a role in resistance to phagocytosis in human blood. This article will provide an overview of
the structure and function of SOF, its role in the pathogenesis of streptococcal infections, its vaccine potential, its prevalence and
distributioninbacteria,andthemolecularmechanismwherebySOFopaciﬁesserumandhowanunderstandingofthismechanism
may lead to therapies for reducing high-cholesterol concentrations in blood, a major risk factor for cardiovascular disease.
1.Introduction
Serum opacity factor (SOF) was ﬁrst discovered in 1938
by the Australians Ward and Rudd [1] as a substance
produced by group A streptococci that caused serum to
become cloudy (Figure 1), hence its name. SOF was found
t oa c to nal i p o p r o t e i nf r a c t i o no fs e r u m[ 2, 3]a n d
various enzymatic activities were proposed to account for
the opacity reaction of SOF including those as a cholesterol
esterase [4] and apolipoproteinase or aspartic protease [5].
Subsequently, SOF was found not to be a hydrolase but
rather induced opaciﬁcation of serum by binding to high-
density lipoproteins (HDLs), displacing apolipoprotein A-I
(apo A-I) and disrupting the structure of HDL resulting in
the formation of large, lipid particles that cause serum to
become opaque [6, 7].
SOF is expressed by a variety of streptococci and
staphylococci including both human and animal pathogens.
SOF is expressed by approximately 50% of the invasive
isolates of the group A streptococcus, Streptococcus pyogenes,
an important human pathogen that colonizes the human
skin and the oral cavity where it may stimulate mild to severe
local inﬂammatory responses resulting in pharyngitis in the
throatandimpetigointheskin[8].Insusceptiblehosts,these
infections can lead to life-threatening complications such as
sepsis, necrotizing fasciitis, and toxic shock, or to debilitating
sequelaesuchasrheumaticfeverandglomerulonephritis[8].
The adhesion to and subsequent colonization of the host
by S. pyogenes have been attributed to a number of surface
exposed molecules including SOF[9]. Furthermore, SOF has
beenfoundtocontributetothepathogenesisofstreptococcal
infections in animal models [10–12]a n dt oe v o k ep r o t e c t i v e
immuneresponsesinhumansandanimals[13]indicatingits
potential as a virulence determinant and vaccine candidate.
SOF is a unique protein exhibiting multiple functions
including not only its ability to opacify serum but also
an ability to bind to a variety of host proteins such as
ﬁbronectin, ﬁbrinogen, and ﬁbulin-1which are involved in2 Journal of Biomedicine and Biotechnology
Figure 1: Opaciﬁcation of human serum by SOF. Human serum
was incubated overnight with either buﬀer control (left) or with
1μg/ml of recombinant SOF (right).
bacterial adhesion. This paper will provide an overview of
the methods of assaying for SOF activity, the structure and
function of SOF, its prevalence and distribution in bacteria,
its role in contributing to the pathogenesis of streptococcal
infections, its vaccine potential, and how investigations into
the mechanisms whereby SOF opaciﬁes serum may lead to
therapies to help control atherosclerosis.
2.Assaysfor DetectingandMeasuring
the Opacity Reaction of SOF
2.1. Soluble Forms of SOF. Whether a particular strain
of bacteria expresses SOF can be determined by several
techniques. Activity of SOF in growth supernatants of
bacteria can be tested by centrifugation of overnight cultures
of the organisms and addition of 100μL of the supernatant
to 1mL of horse serum containing sodium azide to inhibit
bacterial growth. After incubating overnight at 37◦C, the
opaqueness of serum is very visible (illustrated in Figure 1)
and this can be quantiﬁed by measuring the absorbance at
405nm.
SOF activity that is noncovalently associated with the
bacterialsurfacecanbedetectedbyextractingastreptococcal
pellet from 10ml of culture with 0.5ml of 1% SDS and
adding 100μl of the extract to 1ml of horse serum and
recording the absorbance at 405nm after an overnight
incubation at 37◦C. SDS extraction has been shown to be
an accurate and sensitive method for the detection of SOF
activity [14].
Bacterial extracts can also be examined for opacifying
activity by solid agar techniques. One example of this is
the application of bacterial extracts containing SOF to agar
that has been mixed with 50% horse serum [15]. Opacifying
activity is denoted by opaque areas surrounding the applied
sample. Alternatively, extracts containing SOF can be sub-
jected to SDS-PAGE and the SDS-gel is overlaid with agar
containing 50% horse serum [10, 16, 17]. Opacifying activity
is detected by the appearance of opaque bands after a period
of incubation in a moist environment. This last technique
has the advantage over other assays in that active fragments
ofSOFcanbedistinguishedfrominactivefragmentswithout
the need for puriﬁcation.
2.2. Insoluble Forms of SOF. Extraction with SDS will only
removeSOFthatislooselyassociatedwiththesurfaceorSOF
thatisstillinthemembraneandisnotcovalentlyattached.In
fact, only a minor amount of the total SOF is released by SDS
extraction (Courtney et al., unpublished results) as would be
expectedifmostoftheSOFonthestreptococcalsurfacewere
covalently attached via a sortase recognition site. SOF that is
covalently linked to the cell wall can be detected by washing
and suspending the bacteria from 10ml of culture in 1ml of
PBS, adding 100μl of this suspension to 1ml of horse serum
containing 0.2% sodium azide to block bacterial growth and
recording the A405 after an overnight incubation. Negative
controls would include streptococci that do not express SOF
or SOF-negative mutants.
SOF can also be immobilized on surfaces and used in
the opacity reaction. In one example of this type of assay,
plastic tubes were coated with ﬁbronectin and reacted with
SOF,whichbindstoﬁbronectin.Thetubeswerethenwashed
multiple times followed by the addition of horse serum
and incubation for several days. SOF remained bound to
ﬁbronectin and was still able to opacify serum after 3 days
and multiple washes [10]. This suggests that SOF that has
bound to ﬁbronectin-coated surfaces in the host may retain
its ability to opacify serum and such binding may allow SOF
to accumulate in the host during an infection.
2.3. Microtiter Method. For assays in which the amount of
reagents is a limiting issue, a microtiter method can be
used [15]. For example, serum from human donors may
be limited. Puriﬁed lipoproteins are somewhat expensive
and therefore, techniques that reduce the amounts of these
reagents can be cost saving. In a typical assay, 200μlo fs e ru m
or puriﬁed lipoprotein is added to microtiter wells and then
various concentrations of SOF are added. The microtiter
plate should be incubated in a moist environment at 37◦C
and the absorbance at 405nm recorded at timed intervals.
2.4. Substrates for the Opacity Reaction of SOF. Horse serum
is commonly used to measure the opacity reaction of SOF
due to its availability and cost. Variations in the ﬁnal
absorbance values have been noted with diﬀerent lots of
horseserumandotheranimalseraprobablyduetovariations
in the concentration of HDL. Other animal serum may also
beused, however, not allanimal seraworkswithallserotypes
of SOF. For example, SOF from M types 9, 11, 28, and 49
opaciﬁes horse serum, but SOF from these serotypes does
n o tw o r kw e l li nr a b b i ts e r u m[ 18] and there may be other
exampleswhereSOFfromaparticularserotypeofS.pyogenes
does not work well in certain animal sera as this has not been
examined in detail.
Human sera can be used as well but care needs to be
taken to ensure that no neutralizing antibodies are present
in the sera. Antibodies against SOF are found in human
sera due to prior infections with SOF-positive streptococciJournal of Biomedicine and Biotechnology 3
and in some instances these antibodies can neutralize the
opacity reaction of SOF from a particular serotype. In fact,
type-speciﬁc antibodies in serum that neutralize SOF have
been used to serotype strains of S. pyogenes [18–20]. This
form of serotyping was particularly useful for those strains
that were refractory to M protein serotyping and is based
on the ﬁndings that the SOF type-speciﬁc determinants co-
varywiththetype-speciﬁcdeterminantsofMproteins.Thus,
identiﬁcation of the SOF serotype predicted the M serotype
with only a few exceptions [21]. This is mostly of historical
signiﬁcance as strains are currently genotyped by sequencing
the 5  terminus of the emm gene (the gene for M protein).
Puriﬁed HDL can also be used as a substrate for the
opacity reaction of SOF. Other lipoproteins such as very
low-density lipoprotein (VLDL) and low-density lipoprotein
(LDL) are not opaciﬁed by SOF and can serve as negative
controls [6].
It is also important to note that serial dilutions of
extracts with SOF or bacteria should be used in the above
assays, at least initially, as the opaciﬁcation of serum can
b er e d u c e da th i g hc o n c e n t r a t i o n so fS O F .T h u s ,af a l s e
negative or a low value may be obtained if only one
concentrationofextractistestedandthatcontainshighlevels
of SOF. In most opacity assays SOF appears to be optimal
at around 1μg/ml. However, there are many serotypes of
S. pyogenes in which the SOF has not been tested and
there may be some that exhibit a diﬀerent dose response
curve.
3. Structure and Function of SOF
3.1. Structure of SOF. The gene for SOF was ﬁrst cloned
and sequenced by Rakonjac et al. [16] and a repeating
peptide was identiﬁed within this sequence that bound
ﬁbronectin. Kreikemeyer et al. [22] cloned and sequenced
a gene for a ﬁbronectin-binding protein from S. pyogenes
that was subsequently found to be virtually identical to sof
cloned by Rakonjac et al. [16]An u m b e ro fsof genes from
other serotypes were later cloned and sequenced or available
from whole genomes of streptococci (Table 1). Analysis of
the predicted amino acid sequences of SOF indicates that
the leader sequence and the C-terminal regions containing
the ﬁbronectin-binding domain are highly conserved and
there are additional stretches of highly conserved sequences
interspersed among areas of high variation (Figure 2). There
is approximately 40 to 60% homology between SOF from
diﬀerent serotypes of S. pyogenes (Figure 3). Interestingly,
the secondary structure of SOF from diﬀerent serotypes of
S. pyogenes has been remarkably retained even across those
areas of high divergence (Figure 4). However, there is less
similarity between SOF from S. pyogenes and that from S.
dysgalactiae (31% to 38%) and even less with SOF from
S. suis (∼20%) (Figure 3). Note that SOF from S. suis has
been termed OFS (opacity factor of S. suis)[ 11]b u tw e
have retained the term SOF in this review for reasons of
consistency.
Some of the diversity of structure of SOF is related to
its propensity for gene rearrangement. Wertz et al. [31]
identiﬁed several modules of sof that are highly conserved
Table 1: Accession numbers for sof sequences.
SOF serotype Nucleotide sequence
accession numbers References
sof2 AF019890, CP000260 [10, 23]
sof4 AY162273, CP000262 [13, 23]
sof12 AF387738, CP000259 [23, 24]
sof13 AF367016 [17]
sof22a UO2290 [16]
sof28 AF082074, CP000056 [10, 25]
sof49 AF057697, CP000829 [10, 26]
sof61 AF138804, AF139752 direct
submission
sof63 AF191974 [27]
sof75b X83303 [22]
sofVT3.1 AF367012 [17, 28]
sofVT3.2 AF367011 [17]
sofVT21c AF367014 [17]
sofVT37.1 AF367015 [17]
sof90d AF367013 [17]
S. dysgalactiae sof e Z22150 [29]
S. suis sof
AY819647, AB325706
AB325707, AB325708
AB325709, AB325710
[11, 30]
aSequence is identical to that of sof75
bWas initially termed sfb1
cVT indicates virulence typing, a PCR-based genotyping scheme
dAlso termed sofVT2.2
eAlso termed fnbA.
and are duplicated numerous times within sof and contain
invertedrepeats.Suchduplicationsandinversionscanleadto
higher frequencies of recombinational events and variations
in protein sequences that may aid the streptococcus in
escaping immune surveillance.
There are several protein motifs that are conserved in
SOF (Figure 2). A leader sequence that targets proteins for
transport across the membrane is highly conserved among
SOF from various serotypes of S. pyogenes. There are variants
of the leader sequence in SOF from S. suis that in some cases
result in expression of a truncated peptide [30]. There is an
LPXXG anchoring motif that serves as a site for the sortase
enzyme that cleaves SOF and covalently attaches it to the cell
wall [32].
Another conserved domain in SOF is the von Willebrand
FactorA(vWFA)domain,sonamedbecauseitwasoriginally
found in the blood coagulation protein von Willebrand
factor. The vWFA domain is vital for proper control
of hemostasis and thrombosis and a wide spectrum of
other cellular activities, which are mediated primarily by
ligand/receptor interactions [33]. A metal ion-dependent
adhesion site (MIDAS) is found within the vWFA domain
of SOF, as it is in many of the vWFA domains in eukaryotic
proteins. Based on functions of eukaryotic vWFA domains,
this domain in SOF may mediate interactions with host
cell integrins and/or other cellular receptors. Furthermore,4 Journal of Biomedicine and Biotechnology
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Figure 2: A schematic indicating the location of functional domains within SOF. The yellow segments in the top bar indicate regions of
SOF that are highly variable (vary in ≥60% of serotypes), black segments indicate highly conserved regions of SOF (conserved in ≥60%
of serotypes. Only SOFs from S. pyogenes were used to generate this illustration. There are variations in the size of SOF from diﬀerent
serotypes but most are composed of ∼1050 amino acids including the leader sequence. The black lines signify the general location and size
of the indicated domains. Abbreviations: vWFA: von Willebrand Factor A domain, MIDAS: metal ion-dependent adhesion site, Fn/Fgn:
ﬁbronectin/ﬁbrinogen.
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Figure 3: A comparison of the similarity between SOF from various serotypes of S. pyogenes and other streptococci (top). The bottom part
of the ﬁgure illustrates the phylogenetic tree of SOF from diﬀerent streptococci.
because a MIDAS motif is found in all SOFs, metal ions
are likely to be involved in this binding activity. While SOF
is known to mediate streptococcal adhesion/invasion (see
Section 3.2.2), there has been no investigation into the role
of the vWFA domain of SOF in the attachment and invasion
of host cells by streptococci and its function remains to be
resolved.
A repeating peptide is found in the C-terminus of all
SOF from S. pyogenes and S. dysgalactiae that have been
examined to date. This repeating peptide domain binds
ﬁbronectin and it shares homology with a number of
other ﬁbronectin-binding repeat peptides of other bacterial
proteins [9]. However, the C-repeat peptide of SOF from S.
suis has little similarity with that of S. pyogenes and does not
bind ﬁbronectin and its function remains to be determined
[11].
3.2. Functions of SOF
3.2.1. Opaciﬁcation Reaction of SOF. That high-density
lipoprotein(HDL)isthetargetofSOFintheopacityreaction
is supported by the ﬁndings that SOF neither opaciﬁed
human serum depleted of HDL nor serum from apo-AI−/−
mice, which are deﬁcient in HDL [6]. Furthermore, SOF
readilyopaciﬁedpuriﬁedHDLbutdidnotopacifyLDL(low-
density lipoprotein) orVLDL (verylow-density lipoprotein).Journal of Biomedicine and Biotechnology 5
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Figure 4: The predicted secondary structure of SOF is highly con-
served among SOF from diﬀerent serotypes. Only three serotypes
were selected for comparison in order to have a manageable ﬁgure.
Thetopﬁgureindicatesthedegreeofhydrophobicity/hydrophilicity
and the bottom ﬁgure indicates location of helixes, turns, and B-
sheets. The numbering of the amino acids is indicated.
It has been previously suggested that SOF may be an
enzyme with esterase or lipase activity or that it is an aspartic
protease that degrades apo A-I [4, 5, 34]. That SOF is not a
hydrolyticenzymeisindicatedbythefollowingobservations:
(1) Puriﬁed, recombinant SOF did not degrade any of the
apolipoproteinsofHDL;(2)SOFdidnotexhibitanylipolytic
activity; (3) A battery of lipase and protease inhibitors
including an aspartic protease inhibitor had no eﬀect on the
opacity reaction of SOF. Although one inhibitor, dichloro-
isocoumarin, did inhibit the opacity reaction, this was due
to nonspeciﬁc modiﬁcation of amino acids leading to loss
of binding of SOF to HDL and thereby, loss of opacifying
activity [6].
So, if SOF is not a hydrolytic enzyme, then how does
it opacify serum? Clues to a possible mechanism can
be gathered from studies on HDL and its disruption by
chaotropic agents. HDL contains a central core composed
primarily of cholesterol esters and triglycerides surrounded
by a layer of cholesterol, phospholipids, and apolipoproteins
(mainly apo A-I and A-II). These components of HDL
are stabilized by kinetic factors and destabilization can be
induced by detergent, thermal, or chaotropic perturbations
that lead to dissolution of HDL and the concomitant release
of free apo A-I [35–37]. The kinetic stability of HDL is
HDL
CERM
Free apo A-I
CERM
Neo HDL
rSOF
Apo A-I
Apo A-II
Apo E
Figure 5: Model of the opaciﬁcation reaction of SOF with
high-density lipoproteins (HDLs). SOF initiates the opaciﬁcation
reaction by binding to HDL. SOF is a heterodivalent fusogen that
crosslinks two or more HDL particles and simultaneously induces
the release of free apo A-I and promotes the fusion of the resultant
particles culminating in the formation of a cholesterol-ester rich
microemulsion (CERM) and neo-HDL. Neo-HDL is deﬁcient in
freecholesterol/cholesterolestersandrichinphospholipidsandapo
A-II. Some HDL particles also contain apo E, which is preferentially
retained in CERM. Structures are not drawn to scale. CERM
particles range from 100 to 500nm in size whereas HDL particles
are ∼8.5nm [38]. Current data indicates one CERM particle
contains cholesterol-esters from ∼400,000HDL particles. It is these
CERM particles that cause serum to become opaque due to their
large size and insolubility in aqueous solutions.
a measure of the rate at which the particle dissolves and
determines the half life of the particle in solution. Thus,
agents that interfere with the kinetic stability of HDL will
lead to rapid dissolution of the structure of HDL.
SOF binds to HDL with high aﬃnity and according
to chemical kinetics, SOF is a heterodivalent fusogen that
induces the release of free apo-I, the formation of a neo-
HDL particle that contains apo A-I and A-II and is enriched
in phospholipids, and the formation of cholesterol ester-
rich microemulsion (CERM) that fuses to from very large
CERM particles (Figure 5). An electron micrograph of these
particles is shown in Figure 6 and serves to illustrate the
fusion of particles and the formation of large, lipid particles.
It is the formation of these large CERM particles that
causes opaciﬁcation of serum due to their large size and
insolubility in aqueous media. SOF is potent and catalytic
with a 10nM concentration of SOF totally opacifying 8μM
HDL (an 800 fold excess of HDL) in 1 hour at 37◦C. SOF
induces the transfer of nearly all of the neutral lipids of ∼
100,000HDLparticles(∼8.5nmdiameter)toasingleCERM
particle (100–500nM diameter) [7, 38] .Ak e yc o m p o n e n to f
HDL that is required for the opacity reaction is a labile form
of apo A-I and the rate-limiting step in the opacity reaction
is the release of free apo A-I. [39]. Other apolipoproteins6 Journal of Biomedicine and Biotechnology
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Figure 6: Electron micrographs of HDL treated with SOF. Indicated concentrations of rSOF were incubated with human HDL overnight at
37◦C, stained with 2% phosphotungstic acid, and electron micrographs taken at the indicated magniﬁcation.
will not substitute for apo A-I. Murine HDL is opaciﬁed at
faster rate than human HDL and this is most likely due to the
higher hydropathy of human apo A-I as compared to that of
murine apo A-I, which would allow a faster displacement of
murine apo A-I by SOF [39].
3.2.2.RoleofSOFinStreptococcalAdhesionandInvasion. The
twomajorportalsforgroupAstreptococcalinfectionsarethe
tissues of the skin and oral cavity. It has long been recognized
that there are serotypes of S. pyogenes that primarily cause
skin infections, serotypes that primarily infect oral sites, and
serotypes that infect tissues of both the oral mucosa and
skin. SOF is expressed by those serotypes that infect both the
oral epithelium and skin tissues. Thus, SOF may be involved
in the colonization of the host by certain serotypes of S.
pyogenes.
One of the ﬁrst indications that SOF may actually be
involved in streptococcal adhesion was the ﬁnding that SOF
binds to ﬁbronectin [10, 16, 22, 27, 28], an important
component of the extracellular matrix and host surfaces that
has been found to mediate adhesion of a wide variety of
bacteria(Figure 7).AntiserumagainstSOFblockedadhesion
of S. pyogenes to HEp-2 cells suggesting that SOF is involved
in streptococcal adhesion to host cells [40]. SOF was found
toreactwiththeN-terminal,30kDafragmentofﬁbronectin,
the same region of ﬁbronectin that binds to S. pyogenes
[40]. Coating latex beads with SOF promoted adhesion
of these beads to HEp-2 tissue culture cells and also
enhanced phagocytosis of these beads [40]. Gillen et al. [41]
demonstrated that both the C-terminal ﬁbronectin-binding
domain of SOF (FBD) and SOF in which the ﬁbronectin-
binding domain was deleted (SOFΔFn) are involved in
adhesion and invasion of host cells, as both of these forms
mediated adhesion/invasion but not as eﬃciently as full
length SOF. Furthermore, SOFΔFn was more eﬀective than
the C-terminal FBD in promoting adhesion of latex beads
to host cells, but the FBD fragment was more eﬀective in
promotinginvasionofhostcellsbylatexbeadsthanSOFΔFn.
Interestingly, mutations that attenuated the opacity reaction
of SOF had no eﬀect on adhesion indicating that these
functions are separate and distinct [41].
Another ﬁbronectin-binding protein of S. pyogenes is
Sfbx and its gene is found immediately downstream of sof
(Figure 8) and is cotranscribed with sof as a bicistronic
message [24]. Timmer et al. [12] engineered nonpolar
mutants in these two genes in M type 49 S. pyogenes in
order to evaluate their respective roles in host cell invasion.
Inactivation of sof in S. pyogenes caused a 50% reductionJournal of Biomedicine and Biotechnology 7
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and promote internalization of the bacteria [45]. Streptococci and SOF can also bind to Fn that has already bound to surfaces. Hep: heparin,
Fib: ﬁbrin/ﬁbrinogen.
in cellular invasion of HEp-2 tissue culture cells, whereas
inactivation of sfbx had no eﬀect on streptococcal invasion.
Complementation of the SOF-negative defect with a sof
plasmid conferred invasion levels that were higher than the
parent strain. The higher degree of invasion was likely due to
increased expression of sof as it was on a multicopy plasmid.
These data suggest that it is SOF and not Sfbx that is the
major contributor to streptococcal adhesion/invasion. That
inactivation of SOF did not completely eliminate invasion
is most probably due to the fact that S. pyogenes utilizes
multiple adhesins to mediate attachment and invasion [46].
To further compare the roles that SOF and Sfbx may have
ininvasion,plasmidscontainingthesegeneswereintroduced
into Lactobacillus lactis, a bacterium that does not bind
ﬁbronectin nor invade host cells. L. lactis expressing SOF
had 1000-fold increase in host cell invasion as compared to
only a 10-fold increase in L. lactis expressing Sfbx [12]. These
data clearly indicate that SOF mediates invasion of host cells
and is superior to Sfbx in this function. Similar results were
foundwhenthesetwogeneswereintroducedintoMtype1S.
pyogenes, which does not contain either of these genes [12].
The ﬁnding that Sfbx contains a ﬁbronectin-binding
domain homologous to that in SOF yet was not eﬀective
in promoting invasion suggested that ﬁbronectin-binding
domain of SOF may not be involved in host cell invasion by
streptococci and indicates that SOFΔFn region is involved
in this process. This hypothesis was conﬁrmed by the
ﬁndings that complementation of the SOF-negative defect
with SOFΔFn fully restored wild-type levels of invasion
[12]. These data indicate that SOF can mediate streptococcal
invasion of host cells in a ﬁbronectin-independent manner.
A host cell component(s) that could mediate this
ﬁbronectin-independent interaction with SOF was not iden-
tiﬁed in the above studies. Recently, we found that ﬁbulin-1,
a component of the extracellular matrix, binds to SOF and
the ﬁbronectin-binding domain of SOF was not required for
this interaction [49]. Fibulin-1 bound to recombinant SOF
from multiple serotypes suggesting that ﬁbulin-1 binding
domain is likely conserved among SOF from diﬀerent
serotypes. Insertional inactivation of sof diminished ﬁbulin-
1 binding to S. pyogenes by 50%. Puriﬁed SOFΔFn also
blocked binding to S. pyogenes by 45%. These ﬁndings
suggest that SOF is a major but not the only streptococcal
receptor for ﬁbulin-1.
Thus, ﬁbulin-1 could serve as a receptor for SOF that
mediates adhesion of streptococci to surfaces of the host.
Fibulin-1 also binds ﬁbronectin and these two proteins
are found together in the extracellular matrix [50, 51].
Interestingly, full length SOF containing the ﬁbronectin-
binding domain was found to dramatically enhance the
interactions of SOF with a ﬁbronectin-ﬁbulin-collagen com-
plex suggesting that such complexes may be involved in the
adhesion of S. pyogenes to host surfaces [49]. It was proposed
that interactions between collagen and ﬁbronectin induced
a conformational change in ﬁbronectin that promoted
interactions with ﬁbulin-1 and SOF. An illustration of this
complex is provided in Figure 9.
Fibrinogen is another host protein that interacts with
SOF via the β-subunit of ﬁbrinogen [52]. A SOF-negative
mutant bound 50% less ﬁbrinogen than did its wild-type
parent indicating that SOF is a major ﬁbrinogen-binding
protein on S. pyogenes, but not the only one. This is not a
surprising ﬁnding as other streptococcal proteins such as M
proteins and M-related proteins also bind ﬁbrinogen [53].
The ﬁbrinogen-binding domain of SOF was localized to
the same C-terminal repeat domain that binds ﬁbronectin.
Furthermore, ﬁbrinogen blocked the binding of SOF to
ﬁbronectin, indicating that these two proteins bind to the
same domain in SOF. Thus, whether it is ﬁbronectin or
ﬁbrinogen that interacts with SOF will probably depend
upon the local concentration of these two proteins. In blood,
it is likely that ﬁbrinogen will be the major binding protein8 Journal of Biomedicine and Biotechnology
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Figure 8: Variants of the Mga regulon and their relationship to preferential colonization of host sites. Mga (multigene activator) is a positive
regulator of a number of streptococcal genes. The most prominent of these are the family of M proteins whose genes are tandemly linked.
sof and sfbx are bicistronic and are also regulated by Mga, but are located some distance away. emm encodes for M protein, mrp encodes
M-related proteins, ennencodesanM-likeproteinthatbindsIgA,andscpaencodesaC5apeptidase.Someserotypescontainonly mga,emm,
and scpa (pattern A). Other serotypes contain one or more of the remaining genes (patterns B–E). S. pyogenes wi t hM g ap a t t e r n sA ,B ,a n dC
primarily infect oral tissues, whereas strains with pattern D are predominantly found in tissues of the skin. S. pyogenes with a pattern E Mga
regulon are found at both oral and skin sites. Figure derived from data and classiﬁcation scheme of Bessen and co-workers [47, 48].
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Figure 9: Model of quaternary complex between gelatin, ﬁ-
bronectin, ﬁbulin-1, and SOF. Although SOF can bind to ﬁbulin-1
independently of ﬁbronectin, mixed binding experiments indicated
that SOF binds much better to a complex of ﬁbulin-1, ﬁbronectin,
and gelatin. Such complexes are possible because ﬁbronectin
contains independent binding sites for gelatin (collagen), ﬁbulin-
1, and SOF. Also SOF can react with ﬁbulin-1 and ﬁbronectin via
independent binding domains. It is postulated that interactions
betweengelatinandﬁbronectininducesaconformationalchangein
ﬁbronectin that facilitates interactions with other ligands and SOF
and enhances adhesion of streptococci to host surfaces. Reproduced
from [49] with permission.
because the concentration of ﬁbrinogen in blood is ∼10
timeshigherthanﬁbronectin.Fibrinogenisalsofoundinthe
extracellular matrix and it also interacts with ﬁbronectin and
ﬁbulin-1. This raises the question of whethersuch complexes
betweenﬁbronectin,ﬁbrinogen,andﬁbulin-1couldenhance
interactions with SOF to promote streptococcal adhesion.
3.2.3. SOF Is a Virulence Determinant. A comparison of the
survivalcurvesofmicechallengedintraperitoneally(IP)with
an M type 2 strain of S. pyogenes and its SOF-negative
mutant provided the ﬁrst indication that SOF is a virulence
factor [10]. Only 7% of mice challenged IP with wild-
type S. pyogenes survived, whereas 80% of mice survived a
challenge with its SOF-negative mutant. Complementation
of the SOF defect with a plasmid expressing SOF fully
restored virulence as none of the mice challenged with the
complemented strain survived. Subsequent work indicated
that insertional inactivation of sof also inactivated sfbx
[54], a gene for another ﬁbronectin-binding protein that
is cotranscribed with sof. However, it was demonstrated
that the complemented strain expressed SOF and not Sfbx
indicating that it is SOF that is responsible for restoring
virulence [54]. An IP challenge of mice with either a wild-
type M 49 strain of S. pyogenes or its Sfbx-negative mutant
resulted in a death rate of 100%, whereas 25% of the mice
challenged with the SOF-negative mutant survived [12].
H e t e r o l o g o u se x p r e s s i o no fS O Fi na nMt y p e1s t r a i no fS.
pyogenes (an sof and sfbx negative strain) increased mortality
by 25% over that of the wild-type strain, whereas expression
of Sfbx in this same strain had no eﬀect on survival rate [12].
These data suggest that it is SOF and not Sfbx that is the
major contributor to virulence of S. pyogenes.
FurthersupportforSOFasavirulencedeterminantcame
from studies utilizing a murine model of necrotizing skin
infections by S. pyogenes [12]. The skin lesions were larger
in mice challenged with the wild-type strain as compared
those challenged with the SOF-negative mutant. There was
a 7.7-fold increase in the number of cfu obtained from
tissues infected with wild-type strain as opposed to the SOF-
negative mutant. These data again indicate that it is SOF and
not Sfbx that is responsible for virulence and that SOF may
contribute to virulence by enhancing streptococcal invasion
of host tissues.
Another mechanism whereby SOF may contribute to
virulence is by enhancing resistance to phagocytosis inJournal of Biomedicine and Biotechnology 9
blood. Inactivation of sof in M type 4 S. pyogenes decreased
streptococcal survival and growth in human blood [53].
However, inactivation of sof in M type 2 S. pyogenes had
little eﬀect on growth of S. pyogenes in human blood [10].
The reason for this diﬀerence is not clear. It is possible that
the contribution of SOF2 to resistance to phagocytosis is too
slight to make a signiﬁcant impact on growth during the 3
hours of the bactericidal assay, but may be detectable during
a longer time frame. Supporting this possibility is the ﬁnding
that the SOF2-negative mutant was signiﬁcantly less virulent
than its parent in a mouse model of infection after 24 hours
[10]. Furthermore, a small but consistent decrease in the
growth of the SOF2-negative mutant in human blood was
observed in subsequent repeat experiments (Courtney et al,
unpublished data).
Another possibility for why inactivation of sof2 lacked
impact on growth in blood is that M type 2 streptococci may
express other factors that provide a functional redundancy
and thereby mask the loss of SOF2. It is clear, however, that
SOF4 does contribute to resistance of S. pyogenes to phago-
cytosis in human blood. This contribution does not appear
to involve regulating the deposition of complement onto the
streptococcal surface because ablation of sof4 had no impact
oncomplementdeposition.Thus,theantiphagocyticactivity
of SOF may depend on one of its known functions such as its
ability tobind blood proteins suchas ﬁbronectin,ﬁbrinogen,
and ﬁbulin-1, to bind to and disrupt HDL, or it may depend
on some other, as yet unidentiﬁed mechanism(s). Further
work needs to be done to deﬁne the mechanism(s) for
resistance to phagocytosis and to determine if SOF has a role
inresistancetophagocytosisinotherserotypesofS.pyogenes.
S. suis also expresses SOF and inactivation of sof in a
serotype 2 strain resulted in decreased virulence in piglets
challengedintranasally[11].Onlyoneoftheninepiglets(4-5
weekold)challengedwithwild-typeS.suissurvived,whereas
all nine of the piglets challenged with the SOF-negative
mutant survived. An interesting ﬁnding from this study was
that SOF from S. suis did not bind ﬁbronectin. There was
no dramatic diﬀerence between parent and mutant strain
in the colonization of tonsils of infected piglets. However,
inactivation of SOF did appear to reduce the invasiveness of
S. suis in 4-5 week-old piglets. The above ﬁndings have two
implications.First,SOFmaycontributetovirulenceofS.suis
by increasing invasion; second, ﬁbronectin-binding activity
has no role in this activity.
The disruption of the structure of HDL by SOF may
also contribute to the virulence of streptococci. In addition
to its role in reverse cholesterol transport (see Section 7)
HDL has an important role in controlling inﬂammation
due to infections. Inﬂammation stimulated by bacterial
components such as lipopolysaccharide or lipoteichoic acid
is neutralized by HDL [55–57]. HDL reduced mortality in
animal sepsis models and it is thought that HDL helps to
control sepsis and shock by attenuating cytokine responses
to infections [57]. Thus, the dissolution of HDL by SOF
may alter the anti-inﬂammatory activities of HDL. However,
the interactions between free apo A-I and the macrophage
cholesterol exporter ABCA1 were recently found to not
only enhance cholesterol transport but also to suppress
inﬂammation [58]. Thus, disruption of HDL and the release
of free apo A-I by SOF may actually promote an anti-
inﬂammatory response.
HDL also has a role in innate immunity via a number
of antimicrobial agents. HDL contains apo A-I, apo L, and
haptoglobin-related protein, which can kill trypanosomes
[59]. HDL also contains the cathelicidin LL-37, an antimi-
crobial peptide that kills a variety of bacteria including S.
pyogenes [60]. However, LL-37 in a free form can also be
cytotoxic for host cells but this cytotoxicity is inhibited by
lipoproteins in serum [61]. This may be why virtually all of
LL-37inbloodisfoundassociatedwithHDL,LDL,orVLDL.
This raises the question of whether the interaction between
SOF and HDL can release LL-37 and thereby promote its
cytotoxic eﬀects. HDL also contains a surprising number of
complement regulatory proteins and protease inhibitors [62]
but it is not known if the disruption of HDL’s structure by
SOF alters the functions of these proteins.
Although HDL is an antiatherogenic and anti-inﬂam-
matory lipoprotein [63], infections and inﬂammation can
triggereventsthatnotonlyleadtothelossoftheseproperties
of HDL but also convert HDL to a pro-inﬂammatory form
that contributes to the pathogenesis of diseases [64–66].
WhetherSOFmaypromoteorinhibitthisconversionprocess
during infections remains to be determined
4. Regulation of SOF Expression
Expression of SOF in S. pyogenes is controlled by the
multigene activator (Mga, formerly known as VirR and
Mry), which regulates expression of a variety of virulence
factors including M proteins, M-related proteins, Enn, Sic,
and C5a peptidase [67–71]. The primary Mga regulon will
vary among diﬀerent serotypes as illustrated in Figure 8.
In S. pyogenes, the sof gene is cotranscribed with sfbx as a
bicistronic message [24]. Mga is optimally expressed during
log phase of growth and is activated by environmental
signals such as elevated CO2, temperature, and iron-limiting
conditions [72–74].
TheMgapr omot ersar ecat egoriz edbasedonthen umber
and location of Mga-binding sites. The Mga promoter of
sof-sfbx is a category B promoter with an Mga-binding site
that is the most distal found to date while all category A
promoters have a more proximal Mga-binding site [67].
Mga is considered to be a response regulator of a two-
component system but its cognate sensor has not yet been
identiﬁed. Although homologs of Mga have been found in S.
dysgalactiae, it is not known if these also regulate expression
of SOF [71].
5. Distribution of SOF
5.1. Prevalence and Distribution of SOF in Streptococci and
Staphylococci. Table 2 lists the streptococcal and staphylo-
coccal species that either contain the gene for SOF or that
express a functional form of SOF. SOF has been found in
streptococcal groups A, B, C, F, G, and R. Although SOF
was found in some isolates of S. equi and S. agalactiae [75],10 Journal of Biomedicine and Biotechnology
Table 2: Prevalence of SOF among various bacteria.
Bacteria
Number of strains
positive for
SOF/total
a
Reference
Group A streptococcus
S. pyogenes
52/117, 77/125,
51/93 [22, 77, 78]
Group B streptococcus
S. agalactiae 0/14, 0/30, 5/18 [75, 76], ∗
Group C streptococcus
S. equi 4/15, 0/20 [75, 76]
Group D streptococcus
S. bovis, S. equinus,
Enterococcus faecalis b
0/3 [76]
G r o u pFs t r e p t o c o c c u s
S. anginosusc 2/5, 0/5 [75, 76]
Group G streptococcus
S. dysgalactiae, S.
arginosus, S. canis
20/20, 37/68, 0/36 [29, 75, 76]
Group R streptococcus
S. suis 33/36d [30]
Staphylococcus aureus 0/5 ∗
Staphylococcus
epidermidis 3/3 [79]
apositive for sof gene and/or for opaciﬁcation of serum by extracts
bformerly Streptococcus faecalis
cformerly S. milleri,i ti sah e t e r o g e n e o u sg r o u pt h a tm a ya l s oe x p r e s s
group A, C F, or G antigens.
dapproximately 70% of the 33 contained a nonfunctional sof gene.
∗unpublished results from Courtney et al.
Top and Wannamaker [76] found no SOF in 14 isolates
of group B or in 20 isolates of group C. We also did not
ﬁnd SOF in 30 isolates of group B (unpublished data).
These ﬁndings suggest that additional tests need to done to
determine if groups B and C do or do not express SOF. SOF
was not found in streptococcal group D or in Staphylococcus
aureus, but the number of isolates tested was low and further
investigations should be done using a larger number of
isolates. Staphylococcus epidermidis has also been found to
express SOF but only three isolates were tested.
5.2. Streptococcus pyogenes. SOF is expressed by ∼45% of
serotypes of S. pyogenes (Table 3)a n db y∼50% of invasive
isolates[21].ThereareserotypesofS.pyogenesthatprimarily
infect tissues of the oral mucosa and serotypes that primarily
infect skin tissues. A subset of those serotypes that infect
skin tissues express SOF and these serotypes also infect oral
tissues (Figure 8). Approximately 60% of skin strains express
SOF. One of the major diﬀerences between those serotypes
infecting only the skin and those infecting both sites is the
expression of SOF (Figure 8). Thus, acquisition of SOF by
skin strains may have enhanced their ability to colonize the
oral cavity.
5.3. Streptococcus dysgalactiae. As e a r c hf o rg e n e sw i t h
similarity to sof suggested that fnbA of S. dysgalactiae may
also have the capacity to opacify serum. Cloning, expressing,
Table 3: Distribution of SOF among M protein serotypes of S.
pyogenes.
SOF-positive
serotypes
2, 4, 8, 9, 11, 12, 13, 22, 25, 27, 28, 44, 48,
49, 58, 59, 60, 61, 62, 63, 66, 68, 73, 75,
76, 77, 78, 79, 81, 82, 84, 85, 87, 88, 89,
90, 92, 94, 96, 102, 103, 104, 106, 107,
109, 110, 112, 113, 114, 117, 118, 124
SOF-negative
serotypes
1, 3, 5, 6, 14, 15∗, 17, 18, 19, 23, 24, 26,
29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40,
41, 42, 43, 46, 47, 50, 51, 52, 53, 54, 55,
56, 57, 64, 65, 67, 69, 70, 71, 72, 74, 80,
83, 86, 91, 93, 95, 97, 98, 99, 100, 101,
105, 108, 111, 115, 116, 119, 120, 121,
122, 123
Data from Johnson et al. [77]a n dB e a l le ta l .[ 21]. Streptococci are
considered positive if SOF is expressed and/or the sof gene is present.
Note that M types 7, 10, 16, 20, 21, 35, and 45 do not exist as these were
subsequently found not to be group A streptococci.
∗There are conﬂicting reports regarding whether M15 serotypes are
negative or positive for SOF [77, 80].
and testing the recombinant protein of this gene conﬁrmed
that FnbA from S. dysgalactiae is in fact an opacity factor
[10, 27]. FnbA of S. dysgalactiae should not be confused with
FnbA of S. aureus as no opacifying activity has been found
in strains of S. aureus that have been tested and there is
little similarity between these two proteins except for their
ability to bind ﬁbronectin. Southern blot analyses indicated
that fnbA was present in all 20 of the clinical isolates of S.
dysgalactiaetested[29].FnbAthatopaciﬁedhorseserumwas
expressed by S. dysgalactiae, but unlike most strains of S.
pyogenes, only the cell bound form was found and no activity
was found in culture medium [10]. Although these ﬁndings
indicate that fnbA is expressed in S. dysgalactiae, only one
isolatewastestedandadditionalisolatesneedtobeexamined
to determine if expression of SOF is a common trait.
5.4. Streptococcus suis. The group R streptococcus, S. suis,
also expresses SOF [11, 30]. As one might guess from its
name, S. suis is primarily a swine pathogen but it can also
cause infections in humans [81]. Serotype 2 strains of S. suis
are the major cause of infections in both swine and humans.
Thehandlingofpigsorpigproductsandeatingundercooked
pork is associated with high risk for infections. S. suis causes
similar diseases in pigs and humans such as meningitis,
septicemia, pneumonia, endocarditis, arthritis, and sudden
death. SOF was identiﬁed as a virulence factor in a serotype
2s t r a i no fS. suis using a piglet model of infection [11]. The
sof gene was found in 33 of 36 of strains isolated. However,
about 70% of these strains did not express a functional form
of SOF due to point mutations or gene rearrangements [30].
Four allelic variants of sof were found in S. suis [30]. Type 1
and type 2 variants were functionally expressed, whereas the
type3andtype4variantswerenotexpressed.Type3variants
contained a point mutation and type 4 variants contained
insertional elements or exhibited gene rearrangement. The
majority of S. suis isolates that expressed SOF contained the
type 1 allelic variant of sof [30]Journal of Biomedicine and Biotechnology 11
6. Vaccine Potential of SOF
T h ep o t e n t i a lo fS O Fa sav a c c i n ef o rg r o u pAs t r e p t o c o c c a l
infections was ﬁrst highlighted by the ﬁndings that rabbit
antisera against SOF from an M type 2 strain of S. pyogenes
not only opsonized and killed M type 2 S. pyogenes but
also opsonized and killed heterologous M types 4 and 28
of S. pyogenes in human blood [13]. Opsonization and
killing of S. pyogenes in human blood is a key indicator
of an eﬀective vaccine against group A streptococci [82].
These ﬁndings suggest that there are common, protective
epitopes among SOF from diﬀerent serotypes that may
be useful in developing vaccines and that immunization
with these common protective epitopes may confer pro-
tection against a wide variety of SOF-positive serotypes.
Furthermore,antibodiesagainstSOFthatwerepuriﬁedfrom
human serum by SOF-aﬃnity chromatography eﬀectively
killed S. pyogenes in bactericidal assays indicating that
SOF can elicit a protective immune response in humans
[13].
In toxicity studies, mice were intravenously injected with
100μg of SOF or a truncated peptide of SOF and no
overt signs of toxicity were seen [13] .T h e s es a m em i c e
then received an IP injection of 100μg of SOF and again,
without overt signs of toxicity. Subsequent experiments
indicated that these mice were protected against an IP
challenge with S. pyogenes. To determine if the ﬁbronectin-
binding domain of SOF is required to elicit a protective
immune response, mice were immunized subcutaneously
with 25μgo fS O F ΔFn, boosted with 25μgo fS O F ΔFn
two weeks later, and then challenged IP with S. pyogenes.
The results indicated that subcutaneous immunization with
SOFΔFnevokedhightitersagainstSOFinmiceandprovided
signiﬁcant protection against challenging IP infections [13].
Thus, the ﬁbronectin-binding domain of SOF is not required
to stimulate a protective immune response. This does not
mean that the ﬁbronectin-binding domain of SOF could not
c o n t r i b u t et oap r o t e c t i v ei m m u n er e s p o n s eb u tt h a ti ti sn o t
required. Indeed, others have reported that immunization
of mice with the ﬁbronectin-binding domain of SfbI pro-
vided protection against challenge infections of S. pyogenes
[83].
Immunization of mice can evoke a strong antibody
response that can provide protection by several diﬀerent
mechanisms.Antibodiesmayblockadhesiontohostsurfaces
by binding to a surface antigen and interfering with its
ability to interact with host receptors. Antibodies may also
bind to and neutralize a virulence factor or antibodies
may opsonize bacteria. In the case above where mice were
subcutaneously immunized with SOFΔFn, an antiadhesive
eﬀect can be excluded because the mice were challenged IP
which circumvents the stages of adhesion and colonization.
It is possible that protection was aﬀorded by antibodies
that neutralized the function of SOF. However, this is
unlikely because we have not been able to evoke neutralizing
antibodies in any of the animals immunized with SOF
even though high-titered antisera were developed against
SOF. The diﬃculty in developing neutralizing antiserum
against SOF has been noted by other investigators [28].
Thus, the stimulation of opsonic antibodies is the most likely
mechanism for providing protection.
Schulze et al. [84] reported that intranasal immunization
of mice with SOF failed to protect against a lethal mucosal
challenge.Theseﬁndingssuggestthattheintranasalroutefor
administering SOF is not the optimal route for stimulating a
protective immune response, whereas a protective immune
response was evoked by the subcutaneous route. Further
work should be done to determine if other immunization
routes such as intramuscular might be more eﬀective.
The above ﬁndings indicate that SOF contains common
epitopes that can evoke opsonic antibodies that may protect
against infections from a variety of serotypes of SOF-positive
S. pyogenes. Furthermore, anti-SOF serum enhanced the
eﬀectiveness of antiserum against M protein to opsonize and
kill S. pyogenes [13]. This is particularly relevant when one
considers that M proteins from some serotypes did not elicit
av e r ye ﬀective immune response and these serotypes were
primarily SOF-positive [85]. Current vaccine eﬀorts have
focused primarily on M proteins, but the more than 100
diﬀerent types of M proteins complicate vaccine construc-
tion and there are some serotypes whose protective antigens
have not been identiﬁed. Thus, inclusion of common,
protective epitopes of SOF may enhance the eﬀectiveness
of M protein-based vaccines and broaden their coverage of
serotypes.
7. SOF asa Therapeutic to Enhance Reverse
Cholesterol Transport
High-plasma cholesterol levels are considered to be a major
risk factor for cardiovascular disease and much eﬀort has
been given to developing therapies to control cholesterol
concentrations. An important target in this ﬁght to control
cholesterol is the pathway for reverse cholesterol transport
(RCT). RCT is the major pathway for removing cholesterol
from peripheral tissues and transporting it to the liver for
disposal (Figure 10). Defects in this pathway can lead to
the accumulation of cholesterol in macrophages that line
blood vessels resulting in plaque formation and subsequent
atherosclerosis. Thus, therapies that can enhance RCT would
be beneﬁcial in controlling atherosclerosis.
SOF is a heterodivalent fusogen that binds and crosslinks
HDLandinducestheformationofthreemajorproducts:free
apo A-I, CERM particles, and a neo-HDL particle (Figure 5).
All three of these products promote RCT. Free apo A-I is
known to be a potent stimulator of RCT via ABCA1 [89].
Our studies indicate that neo-HDL promotes eﬄux of free
cholesterol from tissues at a faster rate than HDL [88]a n d
this may be due to a new conformational state of apo A-I
that is stabilized by the high percentage of phospholipids in
neo-HDL [90]. In addition, neo-HDL enhances the activity
of lecithin:cholesterol acyl transferase (LCAT) better than
HDL and results in an increase in cholesterol esters in
CERM particles that may aid in removal of cholesterol by
hepatic receptors. Preliminary studies indicate that rSOF
can induce opaciﬁcation of murine HDL in vivo. What is
even more promising is that SOF reduced plasma cholesterol12 Journal of Biomedicine and Biotechnology
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Figure 10: Reverse cholesterol transfer pathway (RCT). RCT is the
majorpathwayfortransferofexcesscholesterol(C)fromperipheral
tissues to the liver for disposal as bile. High levels of cholesterol can
be toxic and the accumulation of cholesterol (C) in macrophages
lining the blood vessels transforms these cells to foam cells leading
to the development of plaque and atherosclerosis. Cholesterol is
removed from these tissues and transferred to HDL by interactions
with ATP binding cassette receptors ABCA1, ABCG1/4, and SR-
B1 or by diﬀusion. The interaction between ABCA1 and apo A-
I is the dominant pathway for removal of excess cholesterol from
macrophages followedbyaninteractionbetween HDLandABCG1.
Together these two receptors account for about 70% of the eﬄux of
excess cholesterol [86]. The size of HDL is modulated as its load
of cholesterol increases and by interactions with various plasma
factorssuchaslecithincholesterolacyltransferase(LCAT)[87].Free
cholesterol removed from these tissues is esteriﬁed by LCAT and
subsequently removed by liver cells by interactions with HDL. SOF
enhances this process in several ways [88]. First, it releases free
apo A-I, which is a better acceptor of free cholesterol than HDL.
Secondly, it forms neo-HDL, a particle that is similar to pre-β HDL,
which is also a better acceptor of cholesterol than HDL. Thirdly,
SOF enhances cholesterol esteriﬁcation, which may allow a more
eﬃcient uptake of cholesterol by the liver.
by 50% in these mice [91]. These observations suggest
that the reaction of rSOF with HDL may have potential
to therapeutically enhance RCT and reduce high levels of
plasma cholesterol that are a leading cause of cardiovascular
disease.
SOF is a virulence factor and it is logical to question
the practicality of using it as a therapeutic. However, there
are examples of bacterial virulence determinants and toxins
that are safely used as therapeutics. Anthrax toxins have
been used to target and kill cancer cells and the isolated
toxins do not pose a health hazard [92]. The botulinum
toxin (Botox) has been used for years as a muscle relaxant
and treatment for facial wrinkles [93]. Streptokinase is a
streptococcal virulence factor that has long been used in
humans as a thrombolytic agent [94]. Thus, while bacterial
virulence factors may contribute to the pathogenesis of
infections, the isolated virulence factor may not necessarily
be harmful when used properly in a puriﬁed form. Previous
studies indicated that an intravenous injection of 100μgo f
rSOF in mice was well tolerated and had no discernable toxic
eﬀects [13] and, as noted above, the cholesterol levels were
dramatically reduced in mice receiving minute quantities
(≤1μg per mouse) of SOF. These are preliminary data and
more deﬁnitive experiments will be required to validate
these initial ﬁndings and to determine the relative bene-
ﬁcial/adverse eﬀects of the interactions between SOF and
HDL
8. FutureConsiderations
It is clear that SOF is a virulence determinant as SOF was
found to contribute to virulence in 3 diﬀerent models of
infection. However, it is not clear which function(s) of SOF
is mainly responsible for this virulence. Mutants defective in
each function of SOF (opaciﬁcation, ﬁbronectin/ﬁbrinogen
binding, ﬁbulin-1 binding, etc.) need to be engineered
and tested in appropriate animal models to determine
which function or combination of functions contributes to
virulence. The role of vWFA domain and its MIDAS motif in
these activities should also be investigated.
As a corollary to these studies, the crystal structure of
SOF needs to be resolved. Establishing the crystal structure
of SOF would help to pinpoint areas for targeting to
create mutant forms of SOF. This information may be used
to engineer forms of SOF that are deﬁcient in activities
contributing to virulence while still maintaining ability to
opacify HDL. In addition to loss of function studies, it may
bepossibletousethestructuralinformationtoengineerSOF
mutants that have a gain of function such as enhanced ability
to opacify serum and thereby to increase concentrations of
the reactants of rSOF-HDL interactions to more eﬀectively
control cholesterol levels via RCT.
The potential of SOF as a vaccine needs to be further
explored. Particularly, in regard to deﬁning the common,
protective epitopes of SOF and determining if a combination
of a SOF vaccine with other vaccines such as M protein
vaccines would broaden coverage of serotypes and enhance
eﬃcacy. SOF is also expressed by animal pathogens and
demonstrated to be a virulence factor in one of these
pathogensbuttherehasbeennoinvestigationintoitsvaccine
potential in animals. Thus, there is a clear need for further
studies on SOF and hopefully, the next decade will bring
exciting, new discoveries about the structure and function
of SOF and will lead to new, highly eﬀective vaccines and
therapeutics.
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